Questcor Pharmaceuticals Inc. (QCOR): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Questcor Pharmaceuticals ( QCOR) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.5%. By the end of trading, Questcor Pharmaceuticals rose $1.02 (1.7%) to $59.94 on average volume. Throughout the day, 1,574,422 shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 1,759,400 shares. The stock ranged in a price between $58.55-$60.34 after having opened the day at $58.84 as compared to the previous trading day's close of $58.92. Other companies within the Health Care sector that increased today were: GW Pharmaceuticals PLC ADR ( GWPH), up 132.5%, Idera Pharmaceuticals ( IDRA), up 24.4%, Edap TMS ( EDAP), up 22.1% and Omeros Corporation ( OMER), up 18.2%.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $3.4 billion and is part of the drugs industry. Shares are up 109.9% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Mast Therapeutics ( MSTX), down 33.1%, Delcath Systems ( DCTH), down 11.9%, Zalicus ( ZLCS), down 11.7% and DARA Biosciences ( DARA), down 10.8% , were all laggards within the health care sector with Celgene Corporation ( CELG) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Cramer: Reviewing S&P's Hit-and-Miss Parade

Cramer: Reviewing S&P's Hit-and-Miss Parade

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015

Greenberg on the Stock Market: Why Investigations No Longer Matter

Greenberg on the Stock Market: Why Investigations No Longer Matter

Retrophin CEO Under Fire for Twitter Faux Pas

Retrophin CEO Under Fire for Twitter Faux Pas

Questcor Pharmaceuticals (QCOR) Hits New Lifetime High Today

Questcor Pharmaceuticals (QCOR) Hits New Lifetime High Today